Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Sort descending Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Sivextro Tedizolid phosphate Acute bacterial skin and skin structure infections Withdrawn
Revestive Teduglutide Short bowel syndrome Reimburse with clinical criteria and/or conditions Complete
Revestive teduglutide Short Bowel Syndrome (SBS), pediatrics Reimburse with clinical criteria and/or conditions Complete
Incivek Telaprevir Hepatitis C, chronic List with clinical criteria and/or conditions Complete
Incivek Telaprevir Hepatitis C, chronic List with criteria/condition Complete
Incivek Telaprevir Hepatitis C, chronic List with criteria/condition Complete
Sebivo Telbivudine Hepatitis B (chronic) Do not list Complete
Twynsta Telmisartan / Amlodipine Hypertension Cancelled
Twynsta Telmisartan/ Amlodipine Hypertension List Complete
Xermelo telotristat carcinoid syndrome Do not reimburse Complete